干扰素γ生物类似药(Pharmaclon)(Interferon gamma biosimilar(Pharmaclon)) - 药物靶点：IFNGR_在研适应症：衣原体感染，乙型肝炎，丙型肝炎_专利_临床

概要

基本信息

药物类型

干扰素、生物类似药

别名

Ingaron

靶点

IFNGR

作用机制

IFNGR刺激剂(干扰素γ受体复合体刺激剂)、ADCC(抗体依赖的细胞毒作用)、免疫刺激剂

治疗领域

肿瘤免疫系统疾病感染+ [5]

在研适应症

衣原体感染乙型肝炎丙型肝炎+ [8]

非在研适应症-

原研机构

Pharmaclon

在研机构

Pharmaclon

非在研机构-

最高研发阶段批准上市

首次获批日期

俄罗斯 (2011-01-01),

衣原体感染乙型肝炎丙型肝炎+ [8]

最高研发阶段(中国)-

特殊审评-

登录后查看首次获批时间轴

关联

7

项与干扰素γ生物类似药(Pharmaclon) 相关的临床试验

NCT06222801 / RecruitingN/AIIT

Open Prospective Observational Cohort Study of the Effectiveness and Safety of Cytokinogenetic Therapy in Patients With Cancer Based on TCTD-1 Patient Registry

Predicting the response of patients diagnosed with cancer to cytokinotherapy is essential to guide anti-tumor therapy complex strategy and subsequent adjuvant approach. Cytokinotherapy is a cost-effective, well-known available method of therapy for the patients with tumors. The objective response possibly correlates to the tumor's size, aggressiveness, age, and other primary factors. Multifactor analysis requires a large amount of data. Therefore, the investigators created the first database aimed to collect data concerning the patients with cancer and the clinical outcomes of cytokinogenetic therapy. The acquired data must be processed to detect the key factors effecting the outcomes. The rationale is that cytokinotherapy is a universal therapeutic approach, although the absence of information that can help personalize it and decrease the rate of progression. The main goal is to find the relationship between initial patients' characteristics and effectiveness of cytokinotherapy for early risks detectioon. The predictive models that can be elaborated from the TCTD-1 analysis will complement knowledge of cytokinotherapy rationale. Predicting survival or other significant clinical criteria using TCTD-1 analysis results would greatly benefit the cancer patients' management.

开始日期2022-09-19

申办/合作机构

NCT06118619 / RecruitingN/A

A Multicenter Clinical Trial of Recombinant Human Interferon Gamma (Ingaron) in Pulmonary Tuberculosis

The main purpose of testing: To confirm the effectiveness and safety of the drug Ingaron when used in patients hospitalized at the research center for various reasons.

开始日期2022-06-01

申办/合作机构

SPP Pharmaclon Ltd.

NL-OMON51150 / RecruitingN/A

QuantiFERON-SARS-CoV-2: performance of an Interferon-Gamma Release Assay for COVID-19 before and after vaccination against SARS-CoV-2 - QFN-SARS: T cell responses pre- and post-vaccination

开始日期2021-06-23

申办/合作机构

QIAGEN Sciences LLC

100 项与干扰素γ生物类似药(Pharmaclon) 相关的临床结果

登录后查看更多信息

100 项与干扰素γ生物类似药(Pharmaclon) 相关的转化医学

登录后查看更多信息

100 项与干扰素γ生物类似药(Pharmaclon) 相关的专利（医药）

登录后查看更多信息

5

项与干扰素γ生物类似药(Pharmaclon) 相关的文献（医药）

2016-11-01·Urologiia (Moscow, Russia : 1999)

[Interferon in combined therapy of human papillomavirus infections associated with sexually transmitted infections. linical observation].

Article

作者: M R Rakhmatulina ; N V Bolshenko

To investigate the effectiveness of Ingaron (interferon-) in the treatment of HPV infection associated with sexually transmitted infections, the authors analyzed the scientific literature on the association of human papillomavirus infection with other viral and microbial pathogens. A clinical case of the association of human papillomavirus infection, urogenital infections (urogenital chlamydia and genital herpes) and localized scleroderma penis is described. The results of integrated therapy of diseases with the help of Interferon-gamma have been presented. According to the literature, up to 70-80% of HPV infections are associated with microbial (opportunistic, obligate pathogens) and viral infectious agents. Chronic inflammation caused by bacterial and viral associations destroys the immune system and it leads to the ineffectiveness of the therapy. Pathogenic therapy of sexually transmitted infections in combination with interferon-gamma (Ingaron) contributes to the eradication of bacterial pathogens, prevention of viral STI recurrence and elimination of high oncogenic risk types of HPV. Thus, we can reasonably infer that Ingaron (interferon-) alleviates the initial immune disturbances, improves the effectiveness of the treatment and may be recommended for treating HPV infection associated with sexually transmitted infections.

2016-08-01·Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic]

Interferon-Gamma: Treatment Horizons.

Review

作者: A A Khryanin ; O V Reshetinikov

The review provides modern literature data on the system of interferons, their cells producers and target cells. Particular attention is paid to the immunomodulating effect of interferon-y. High efficacy of Ingaron in the treatment of various groups of diseases, especially viral, infectious and oncologic is shown.

2015-01-01·Voprosy virusologii

[Evaluation of the antiviral therapy for chronic hepatitis C in patients unresponsive to previous treatment with regard to the interleukin-28B genotypes].

Article

作者: V Ch Fazylov ; S V Tkacheva ; E R Manapova ; F M Jakupova

The identification of the single nucleotide polymorphisms (SNP) at rs8099917 and rs12979860 loci of IL-28B gene is presently necessary for patients with the genotype HCV-1 to predict sustained viral response (SVR) in case of combined antiviral therapy with interferon and ribavirin. In addition to the implementation of the antiviral activity of IFN-α, interleukin-1β (IL-1β) and interferon-gamma (IFN-γ) are involved. The goal of this work was to evaluate the efficacy of the HCV therapy with cytokines in patients unresponsive to previous therapy with unfavorable genotypes of IL-28B gene. SVR was achieved in 44.4% of patients with an unfavorable IL-28B genetic background with biochemical response without serious adverse effects or unexpected adverse effects, thereby corroborating the inclusion of proven safety Betaleukin® and Ingaron in the schemes of the antiviral therapy in combination with standard interferon-α and ribavirin in patients with recurrent HCV-infection.

100 项与干扰素γ生物类似药(Pharmaclon) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	L03AB03	-

研发状态

适应症	最高研发状态	国家/地区	公司
肺结核	批准上市	俄罗斯更多	Pharmaclon 更多
乙型肝炎	批准上市	俄罗斯更多	Pharmaclon 更多
衣原体感染	批准上市	俄罗斯更多	Pharmaclon 更多
HIV感染	批准上市	俄罗斯更多	Pharmaclon 更多
新生儿呼吸窘迫综合征	批准上市	俄罗斯更多	Pharmaclon 更多

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


P376 (EBMT2018)	N/A	造血干细胞移植 interferon-gamma	27	Interferon-Gamma	簾網壓憲襯範繭網鹽構(遞鏇艱顧顧衊願淵窪膚) = 獵餘簾構願淵鹽網衊鑰遞衊淵糧餘獵壓築鑰餘 (築壓製鏇夢鹽鏇糧願範 )	积极	2018-11-19
				Interferon-Gamma	簾網壓憲襯範繭網鹽構(遞鏇艱顧顧衊願淵窪膚) = 醖衊膚積鏇艱鹽齋衊醖遞衊淵糧餘獵壓築鑰餘 (築壓製鏇夢鹽鏇糧願範 )
ASCO2014	N/A	卵巢癌新辅助	54	Ingaron	(廠淵鏇獵齋遞艱網窪糧) = 遞鏇糧範遞願齋選顧顧夢積鹹憲夢衊顧廠繭範 (艱觸齋觸鑰糧醖膚窪願 ) 更多	积极	2014-05-20
				CAP chemotherapy without Ingaron	(廠淵鏇獵齋遞艱網窪糧) = 簾鏇醖獵鑰醖鹹齋餘蓋夢積鹹憲夢衊顧廠繭範 (艱觸齋觸鑰糧醖膚窪願 )
ASCO2020	N/A	卵巢癌新辅助	-	CT with carboplatin and paclitaxel	(夢憲觸築鑰蓋憲遞顧鹹) = 顧網築廠顧艱願窪選鹹廠廠膚簾構築膚積醖膚 (遞衊觸鬱艱鏇窪遞壓窪 ) 更多	积极	2020-05-25
				Chemoimmunotherapy and intramuscular IFN-gamma (ingaron)	(遞壓窪齋積築觸範顧餘) = 廠構醖鏇衊鏇網範築鏇淵積遞鏇觸醖夢廠遞繭 (選願構積夢鑰襯膚積顧, p≤0.05) 更多
ARVO2003	N/A	视网膜星形细胞瘤 interferon-gamma \| tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)	-	Interferon-Gamma	(淵鹽鹹製鏇顧製鏇膚窪) = 鑰夢積繭餘築鏇淵構淵餘選艱淵觸壓蓋鬱簾鏇 (膚廠積積鹽獵願選衊範 )	-	2003-05-01
IAS2008	N/A	肺结核	-	IFN-g injection (Ingaron)	(積衊齋艱選憲鹹蓋淵糧) = 遞膚廠鹹憲艱鏇醖獵觸築網憲築積窪鑰壓鏇構 (壓鬱鏇鑰簾鏇淵願積齋 )	积极	2008-01-01